Search
Killer antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read moreFirst randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read moreEHA Pediatric Hemato-Oncology Course programme
April 10, 202414:00–17:30: Red Cell and ConsultativeWelcome and presentation of the course. Aims, expectations, and a brief look back. Presenters and topics
M. de Montalembert: Difficult management problems in sickle cell disease
M. D.
EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders
EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.
Read morePosition of EHA on Clinical Trials
The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.
EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding
Meeting chairs, Carlo Balduini and Anna Falanga
The meeting was well attended by more than 100 participants coming from over 20 different countries
Delegate: Great meeting.
EPICOVIDEHA survey
COVID-19 infections in patients with Hematological Malignancies - Results from EHA-IDWP registry
EPICOVIDEHA is an international open web-based registry for patients with haematological malignancies infected with SARS-CoV-2,
The survey has been approved by the Institutional Review Board and Ethics Committee of the…